Entries by Thomas Gabrielczyk

CPhI sheds light on future markets

With  about 38,000 attendees and 2,500 exhibitors, CPhI worldwide in Barcelona has broken another record. Personalised 3D printed pills and hypothesis generation using big data were only two trends reported.

Update: Immunic bags €17.5m

Martinsried-based autoimmune specialist Immunic AG secured financial support for the next 3.5 years from lead investors Life Sciences Partners and LifeCare Partners (LCP, Switzerland) based on prior autoimmune programmes of 4SC AG.

iOmx hits the ground running

Backed by MPM Capital and Sofinnova, immuno-oncology specialist iOmx Therapeutics has raised €40m in its first round of financing. The German company had just been founded in spring.

Exosomes: Extracellular and extraordinary

Disregarded for decades, extracellular vesicles are now understood to be a key element in communication between cells. Discoveries around the nano-sized bubbles are revolutionising not only the field of diagnostics. With their ability to mimic stem cells, EVs could also help open the doors to novel therapeutic concepts. 

Sepsis: Targeting a silent killer

For over three decades, attempts among drug developers to target the inflammatory pathways and symptoms of sepsis have been fruitless. New rapid diagnostics, rigourous patient stratification and drugs with novel modes of action are now on the horizon for treating the most costly cause of death in the industrialised world. Biotechs are pushing new ideas towards clinical testing, but there just isn’t enough funding available in the EU. Will US investors again pick up European innovation on the cheap?